Systemic Lupus Erythematosus Treatment Guidelines

Core Treatment Principles

Universal Baseline Therapy

• The 2024 EULAR recommendations establish that all SLE patients should receive hydroxychloroquine (≤5 mg/kg real body weight) as the foundation of therapy, with treatment goals targeting remission or low disease activity (SLEDAI ≤4, PGA≤1, prednisone ≤7.5 mg/day) rather than simply controlling symptoms 1

• Hydroxychloroquine is mandatory for all SLE patients unless contraindicated, as it reduces disease activity, flares, organ damage, and mortality 2

• The maximum hydroxychloroquine dose is 5 mg/kg of actual body weight (typically 200-400 mg daily) 2

Treatment Goals (Treat-to-Target Approach)

• Complete remission is defined as no clinical activity without glucocorticoids or immunosuppressants 2

• Low disease activity (LLDAS) is defined as SLEDAI ≤4, PGA≤1, prednisone ≤7.5 mg/day on well-tolerated immunosuppressants [2] [1]

• Both remission and low disease activity states show comparable outcomes in preventing organ damage and flares, though remission may have slightly lower damage accrual 1

Glucocorticoid Management

Acute/Severe Disease

• For organ-threatening manifestations, administer IV methylprednisolone 500-2500 mg total (250-1000 mg/day for 1-3 days) 3

• Initial oral prednisone dosing is 0.3-0.5 mg/kg/day (lower than historical 0.5-1 mg/kg/day based on recent evidence) 3

Tapering Strategy

• Rapidly taper to ≤7.5 mg/day prednisone within 3-6 months, with the goal of complete withdrawal [2] [3]

• Chronic maintenance should not exceed 7.5 mg/day prednisone equivalent 2

• Recent trials (CORTICOLUP, WIN-LUPUS) support discontinuation strategies in stable patients, though with higher relapse rates 1

Immunosuppressive Therapy

Moderate to Severe Non-Renal SLE

• Add immunosuppressants when disease cannot be controlled with hydroxychloroquine and low-dose glucocorticoids 2

• First-line immunosuppressive options include methotrexate, azathioprine, or mycophenolate mofetil 2

Lupus Nephritis (Class III-IV)

Induction Therapy

• For lupus nephritis induction, use mycophenolate mofetil 2-3 g/day (or mycophenolic acid 1.44-2.16 g/day) OR low-dose IV cyclophosphamide (500 mg every 2 weeks × 6 doses) 3

• Both mycophenolate and low-dose cyclophosphamide regimens show similar efficacy; mycophenolate may be more effective in African-Americans 3

• Administer IV methylprednisolone 500-2500 mg total, followed by oral prednisone 0.3-0.5 mg/kg/day, tapering to ≤7.5 mg/day by 3-6 months 3

• High-dose IV cyclophosphamide (0.5-0.75 g/m² monthly × 6 months) is indicated for patients with adverse prognostic factors (crescents/necrosis in >25% glomeruli, GFR 25-80 mL/min) 3

• Tacrolimus alone or combined with mycophenolate is an alternative induction option 3

Maintenance Therapy

• Maintain lupus nephritis patients on mycophenolate mofetil or azathioprine for at least 3 years 3

• Continue hydroxychloroquine throughout lupus nephritis treatment 3

Treatment Goals for Lupus Nephritis

• Evidence of improvement should be seen by 3 months (decreasing proteinuria, stable/improving GFR) 3

• Partial response by 6 months is defined as ≥50% reduction in proteinuria to subnephrotic levels, with creatinine within 10% of baseline 3

• Complete response by 12 months is defined as proteinuria <0.5-0.7 g/24 hours 3

• For nephrotic-range proteinuria at baseline, extend treatment response timeframes by 6-12 months 3

Biologic Therapies

Belimumab

• Belimumab is indicated as add-on therapy for persistently active or flaring disease despite standard therapy 1

• High-quality RCT evidence supports belimumab efficacy in both active SLE and lupus nephritis 1

Anifrolumab

• High-quality RCT evidence demonstrates anifrolumab efficacy in active SLE 1

Voclosporin

• High-quality RCT evidence supports voclosporin use for lupus nephritis 1

Monitoring and Disease Assessment

Disease Activity Monitoring

• Use validated activity indices (SLEDAI, BILAG) at each visit 2

• Monitor complement levels (C3, C4) and anti-dsDNA antibodies 2

• For lupus nephritis, monitor urine protein-creatinine ratio, serum creatinine, and urine sediment 3

Comorbidity Management

Antiphospholipid Syndrome

• Screen all SLE patients at diagnosis for antiphospholipid antibodies 2

• For high-risk antiphospholipid antibody profile (persistently positive medium/high titers or multiple positivity), consider low-dose aspirin for primary prophylaxis, especially with other cardiovascular risk factors 2

• For secondary prevention after thrombosis, treat as primary antiphospholipid syndrome with long

Guidelines for Managing Lupus Membranous Glomerulonephritis (LMN)

Hydroxychloroquine Dosing and Safety

• In all patients with systemic lupus erythematosus (including those with lupus nephritis), hydroxychloroquine should be limited to a maximum of 5 mg/kg of actual body weight per day to minimise the risk of retinal toxicity. 4

Glucocorticoid Induction Regimen

• For organ‑threatening manifestations of active lupus nephritis, intravenous methylprednisolone bolus of 250–1000 mg per day for 1–3 days is recommended as the initial pulse. 4
• After the pulse, oral prednisone should be tapered rapidly to ≤7.5 mg per day within 3–6 months, with the aim of complete discontinuation when disease control permits. 4
• Chronic glucocorticoid therapy must never exceed 7.5 mg prednisone‑equivalent per day, as higher doses markedly increase the risk of irreversible organ damage. 4

Therapeutic Goals and Response Assessment

• The primary therapeutic objective is to achieve at least a partial renal response within 6–12 months, defined as a ≥50 % reduction in proteinuria to sub‑nephrotic levels and serum creatinine remaining within 10 % of baseline. 4
• A partial response at 6 months is characterised by the same ≥50 % proteinuria reduction and stable or improved renal function (creatinine within 10 % of baseline). 4

Monitoring and Adherence

• Measurement of hydroxychloroquine blood concentrations can be employed to assess patient adherence to therapy. 4

Glucocorticoid Toxicity Avoidance

• Chronic glucocorticoid doses greater than 7.5 mg per day should be avoided because they substantially raise the risk of irreversible organ damage. 4